Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Date publication

mai 2015

Journal

Neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LHERMITTE Benoît

Tous les auteurs :
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25762461

Résumé

Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the selective integrin inhibitor cilengitide combined with standard chemoradiotherapy in patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter.

Mots clés

Adult, Aged, Antineoplastic Agents, adverse effects, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, drug therapy, DNA Methylation, DNA Modification Methylases, genetics, DNA Repair Enzymes, genetics, Dacarbazine, analogs & derivatives, Female, Glioblastoma, drug therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Promoter Regions, Genetic, Snake Venoms, adverse effects, Treatment Outcome, Tumor Suppressor Proteins, genetics

Référence

Neuro-oncology. 2015 May;17(5):708-17